Skip to main content
SpringerLink
Log in

Plasmacytoma—Current Approach to Diagnosis and Management

  • Chapter
  • First Online:
Biology and Management of Unusual Plasma Cell Dyscrasias

Abstract

About 3–5 % of patients with plasma cell dyscrasias present with either a single bone lesion, or less commonly, a soft tissue mass made up of monoclonal plasma cells without evidence of bone marrow involvement or end-organ damage known as a solitary plasmacytoma (SP). SP of bone mostly occurs in axial skeleton, while it most often affects the head and neck region in case of extramedullary tumors. Their median age is 55 years and mostly present with bony pain, spinal cord, or nerve root compression. A whole body (WB) or spine and pelvic magnetic resonance imaging (MRI) scan or WB fluorodeoxyglucose–positron emission tomography (FDG–PET) scan should be included in staging of these patients. The standard of care for SP is radiotherapy (RT) given with curative intent. Surgery may be required for patients with retropulsed bone, structural instability of the bone, or rapidly progressive neurological symptoms from spinal cord compression. The role of adjuvant RT after complete surgical resection, adjuvant chemotherapy, or adjuvant bisphosphonates is not well defined and hence not recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Google Scholar 

  2. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037.

    CAS  PubMed  Google Scholar 

  3. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.

    Google Scholar 

  4. Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

    Google Scholar 

  5. Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol. 2002;3(3):255–9.

    Article  PubMed  Google Scholar 

  6. Wiltshaw E. The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine. 1976;55(3):217–38.

    Article  CAS  PubMed  Google Scholar 

  7. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–14.

    Article  CAS  PubMed  Google Scholar 

  8. Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000;85(1):47–51.

    CAS  PubMed  Google Scholar 

  9. Hughes M, Doig A, Soutar R. Solitary plasmacytoma and multiple myeloma: adhesion molecule and chemokine receptor expression patterns. Br J Haematol. 2007;137:486.

    Article  PubMed  Google Scholar 

  10. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol. 2001;115, 522–540.

    Google Scholar 

  11. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004. Br J Haematol. 2009;144(1):86–94.

    Article  PubMed  Google Scholar 

  12. Shih LY, Dunn P, Leung WM, et al. Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer. 1995;71:128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Frassica DA, Frassica FJ, Schray MF, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16:43.

    Article  CAS  PubMed  Google Scholar 

  14. McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. J Spinal Disord. 1989;2:69–74.

    Article  CAS  PubMed  Google Scholar 

  15. Bataille R, Sany J. Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer. 1981;48:845.

    Article  CAS  PubMed  Google Scholar 

  16. Vaicys C, Schulder M, Wolansky LJ, Fromowitz FB. Falco-tentorial plasmacytoma. J Neurosurg. 1999;91:132–5.

    Article  CAS  PubMed  Google Scholar 

  17. Vijaya-Sekaran S, Delap T, Abramovich S. Solitary plasmacytoma of the skull base presenting with unilateral sensorineural hearing loss. J Laryngol Otol. 1999;113:164–6.

    Article  CAS  PubMed  Google Scholar 

  18. Burt M, Karpeh M, Ukoha O, et al. Medical tumors of the chest wall: solitary plasmacytoma and Ewing’s sarcoma. J Thorac Cardiovasc Surg. 1993;105:89–96.

    CAS  PubMed  Google Scholar 

  19. Gerry D, Lentsch EJ. Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. Otolaryngol Head Neck Surg. 2013;148:974.

    Article  PubMed  Google Scholar 

  20. Han YJ, Park SJ, Park MI, Moon W, Kim SE, Ku KH, Ock SY. Solitary extramedullary plasmacytoma in the gastrointestinal tract: report of two cases and review of literature. Korean J Gastroenterol. 2014;63(5):316–20.

    Article  PubMed  Google Scholar 

  21. Shaikh G, Sehgal R, Mehrishi A, Karnik A. Primary pulmonary plasmacytoma. JCO 2008;26(18):3089–91.

    Google Scholar 

  22. Kim SH, Kim TH, Sohn JW, Yoon HJ, Shin DH, Kim IS, Park SS. Primary pulmonary plasmacytoma presenting as multiple lung nodules. Korean J Intern Med. 2012;27(1):111–3.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Feng PH, Huang CC, Wang CW, Wu YK, Tsai YH. Solitary pleural plasmacytomas manifested as a massive pleural effusion without evidence of monoclonal gammopathy. Respirology. 2008;13(5):751–3.

    Article  PubMed  Google Scholar 

  24. Lee JY, Won JH, Kim HJ, et al. Solitary extramedullary plasmacytoma of the liver without systemic monoclonal gammopathy. J Korean Med Sci. 2007;22(4):754–7.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Bigé N, Arnulf B, Hummel A, Keyser ED, Royal V, Buzyn A, Fakhouri F. Urinary tract obstruction due to extramedullary plasmacytoma: report of two cases. NDT Plus. 2009;2(2):143–6.

    PubMed  PubMed Central  Google Scholar 

  26. Rosenberg S, Shapur N, Gofrit O, Or R. Plasmacytoma of the testis in a patient with previous multiple myeloma: is the testis a sanctuary site? JCO 2010;28(27):e456–8.

    Google Scholar 

  27. Shakuntala PN, Praveen SR, Shankaranand B, Rajshekar K, Umadevi K, Bafna UD. A rare case of plasmacytoma of the ovary: a case report and literature review. Ecancermedicalscience. 2013;7:288.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Tüting T, Bork K. Primary plasmacytoma of the skin. J Am Acad Dermatol. 1996;34(2 Pt 2):386–90.

    Article  PubMed  Google Scholar 

  29. Menke DM, Horny HP, Griesser H, et al. Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol. 2001;115:119–26.

    Article  CAS  PubMed  Google Scholar 

  30. Wavre A, Baur AS, Betz M, et al. Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma. Neuro Oncol. 2007;9(3):370–2.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Pambuccian SE, Horyd ID, Cawte T, Huvis AG. Amyloidoma of bone, a plasma cell/plasmacytoid neoplasm. Report of three cases and review of the literature. Am J Surg Pathol. 1997;21:179–86.

    Article  CAS  PubMed  Google Scholar 

  32. Nagasaka T, Lai R, Kuno K, Nakashima T, Nakashima N. Localised amyloidosis and extramedullary plasmacytoma involving the larynx of a child. Hum Pathol. 2001;32:132–4.

    Article  CAS  PubMed  Google Scholar 

  33. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.

    Article  CAS  PubMed  Google Scholar 

  34. Hughes M, Soutar R, Lucraft H, Owen R, Bird J, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas: 2009 update.

    Google Scholar 

  35. Warsame R, Gertz MA, Lacy MQ, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87:647.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Rawstrom AC, Orfao A, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. 2008;93:431–8.

    Google Scholar 

  37. Guidelines Working Group of the UK Myeloma Forum (UKMF). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717–26.

    Article  Google Scholar 

  38. Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol). 2004;16:405–13.

    Article  Google Scholar 

  39. Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, Gertz MA, Therneau TM, Melton JL, Dispenzieri A, Katzmann JA. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Guillemette F, Guidez S, Herbaux C et al. Impact of Initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20(12).

    Google Scholar 

  41. Walker RC, Jones-Jackson LB, Rasmussen E, et al. PET and PET/CT imaging in multiple myeloma, solitary plasmacytoma, MGUS, and other plasma cell dyscrasias. Positron Emiss Tomogr. 283–302.

    Google Scholar 

  42. Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657.

    Article  PubMed  Google Scholar 

  43. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. JCO. 1993;11(7):1311–5.

    CAS  Google Scholar 

  44. Liebross RH, Ha CS, Cox JD, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:1063–7.

    Article  CAS  PubMed  Google Scholar 

  45. Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184:1199–204.

    Article  PubMed  Google Scholar 

  46. Lu YY, Chen JH, Lin WY, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37:833–7.

    Article  PubMed  Google Scholar 

  47. Schrirrmeister H, Buck AK, Bergmann L, Reske SN. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm. 2003;18:841–5.

    Article  Google Scholar 

  48. Pertuiset E, Bellaiche L, Lioté F, Laredo JD. Magnetic resonance imaging of the spine in plasma cell dyscrasias. A review. Rev Rhum Engl Ed. 1996;63:837.

    CAS  PubMed  Google Scholar 

  49. Kim PJ, Hicks RJ, Wirth A, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2009;74:740.

    Article  CAS  PubMed  Google Scholar 

  50. Nanni C, Rubello D, Zamagni E, et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22(4):513–7.

    Google Scholar 

  51. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–5.

    Article  PubMed  Google Scholar 

  52. Salaun PY, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bodere-Kraeber F. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica Hematol J. 2008;93(8):1269–71.

    Article  Google Scholar 

  53. Chak LY, Cox RS, Bostwick DG, et al. Solitary plasmacytoma of bone: treatment, progression, and survival. J Clin Oncol. 1987;5:1811–5.

    CAS  PubMed  Google Scholar 

  54. Tsang RW, Gospodarowiez MK, Pintille M, et al. Solitary plasmacytoma treated with radio therapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50:113–20.

    Article  CAS  PubMed  Google Scholar 

  55. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002;94:1532–7.

    Article  CAS  PubMed  Google Scholar 

  56. Knobel D, Zhouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6, article 118.

    Google Scholar 

  57. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter rare cancer network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–7.

    Article  PubMed  Google Scholar 

  58. Kilciksiz S, Celik OK, Pak Y, et al. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group—Sarcoma Working Party. Am J Hematol. 2008;83(9):702–7.

    Article  PubMed  Google Scholar 

  59. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1:255–62.

    CAS  PubMed  Google Scholar 

  60. Soesan M, Paccagnella A, Chiarion-Sileni V, et al. Extramedullary plasmacytoma. Clinical behaviour and response to treatment. Ann Oncol. 1992;3:51–7.

    CAS  PubMed  Google Scholar 

  61. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52(3):245–9.

    Article  CAS  PubMed  Google Scholar 

  62. Strojan P, Soba E, Lamovec J, Munda A. Extramedullary plasmacytoma: clinical and histopathologic study. Int J Radiat Oncol Biol Phys. 2002;53(3):692–701.

    Article  PubMed  Google Scholar 

  63. Chao MC, Gibbs P, Wirth A, Quong G, Guiney MJ, Liew KH. Radiotherapy in the management of solitary extramedullary plasmacytoma. Intern Med J. 2005;35(4):211–5.

    Article  CAS  PubMed  Google Scholar 

  64. Mendenhall CM, Thar TL, Million RR. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1980;6:1497–501.

    Article  CAS  PubMed  Google Scholar 

  65. Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, Mege A, Dolivet G, Toussaint B, Charra-Brunaud C, Hoffstetter S, Marchal C, Peiffert D. Radiotherapy for solitary extramedullary plasmacytoma in the head and neck region: a dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys. 2006;64:1013–7.

    Article  PubMed  Google Scholar 

  66. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A, et al. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;Article ID 895765.

    Google Scholar 

  67. Alexanian R. Localized and indolent myeloma. Blood. 1980;56:521–6.

    CAS  PubMed  Google Scholar 

  68. Fang Z, Yi X, Zhu T. Anterior approach to the second thoracic vertebral body for surgical treatment (vertebrectomy, bone grafting and titanium alloy plate fixation). Int J Clin Oncol. 2001;6:205–8.

    Article  CAS  PubMed  Google Scholar 

  69. Muhlbauer M, Pfisterer W, Eyb R, Knosp E. Noncontiguous spinal metastases and plasmacytomas should be operated on through a single posterior midline approach, and circumferential decompression should be performed with individualized reconstruction. Acta Neurochir (Wien). 2000;142:1219–30.

    Article  CAS  Google Scholar 

  70. Jantunen E, Koivunen E, Putkonen M, et al. Autologous stem cell transplantation in patients with high risk plasmacytoma. Eur J Haematol. 2005;74:402–6.

    Article  CAS  PubMed  Google Scholar 

  71. Aviles A, Huerta-Guzman J, Delgado S. Improved outcome in solitary bone plasmacytomata with combined therapy. Haematol Oncol. 1996;14:111–7.

    Article  CAS  Google Scholar 

  72. Holland J, Trenkner DA, Wasserman TH, Fineberg BL. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69:1513–7.

    Article  CAS  PubMed  Google Scholar 

  73. Delauche-Cavallier MC, Laredo JD, Wybier M, et al. Solitary plasmacytoma of the spine: long-term clinical course. Cancer. 1988;61(8):1707–14.

    Article  CAS  PubMed  Google Scholar 

  74. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009;20:1303–17.

    Article  CAS  PubMed  Google Scholar 

  75. http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.

  76. Creach KM, Foote RL, Neben-Wittich MA, Kyle RA. Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys. 2009;73:789.

    Article  PubMed  Google Scholar 

  77. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: implications for progression to overt multiple myeloma. Hematology. 1997;11(1):71–87.

    CAS  Google Scholar 

  78. Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996;36(2):329–33.

    Article  CAS  PubMed  Google Scholar 

  79. Weber DM. Solitary bone and extramedullary plasmacytoma. Am Soc Hematol Edu Book. 2005;373–376.

    Google Scholar 

  80. Susnerwala SS, Shanks JH, Banerjee SS. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997;75(6):921–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003;101(5):1715–7.

    Article  CAS  PubMed  Google Scholar 

  82. Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117:4468–74.

    Article  PubMed  Google Scholar 

  83. Jackson A, Scarffe JH. Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone. Eur J Cancer. 1990;26:363–71.

    Article  CAS  PubMed  Google Scholar 

  84. Mayr NA, Wen BC, Hussey DH, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol. 1990;17:293–303.

    Article  CAS  PubMed  Google Scholar 

  85. Dimopouloos MA, Papadimitriou C, Anagnostopoulos A, Mitsibounas D, Fermand JP. High dose therapy with autologous stem cell transplantation for solitary plasmacytoma complicated by local relapse or isolated distant recurrence. Leuk Lymphoma. 2003;44:153–5.

    Article  Google Scholar 

  86. UK Myeloma Forum and the Nordic Study Group. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol. 2005;132:410–51.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55902, USA

    Nidhi Tandon MD

  2. Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55902, USA

    Shaji K. Kumar MD

Authors
  1. Nidhi Tandon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaji K. Kumar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaji K. Kumar MD .

Editor information

Editors and Affiliations

  1. Section of Hematology/Oncology MC2115, University of Chicago, Chicago, USA

    Todd M. Zimmerman

  2. Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA

    Shaji K. Kumar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tandon, N., Kumar, S.K. (2017). Plasmacytoma—Current Approach to Diagnosis and Management. In: Zimmerman, T., Kumar, S. (eds) Biology and Management of Unusual Plasma Cell Dyscrasias. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6848-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-6848-7_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-6847-0

  • Online ISBN: 978-1-4419-6848-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation